Board summary
Key figures
42,016
Registered population
59.9% aged 18–64
20.5%
Aged 65+
ICB 19.9% · England 17.9%
11.1%
Ethnic minority (non-White)
6.1% Asian · England 9.6%
38.5%
In IMD quintile 1
ICB 17.1% · England 21.0%
~15,711
Core20 residents (est.)
Resident basis; registered basis ~16,602 · see page 3
6,933
Hypertension register
+7.44% in 3 yrs · England +5.60%
681
SMI register
48.2% of Folkestone and Hythe's
1,181
COPD register
Reviews +17.61% in 3 yrs
Forecast to 2030
8,352
Hypertension patients, 2030
+1,419 on today
61.3%
QRISK ≥20% on statins, 2030
+2.10pp over 3 yrs
5.2%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma annual reviews fall behind England.
Asthma annual reviews fell 8.3% over 2023 to 2025 to 57.2% (England 65.7%), leaving an estimated 1,155 scale on the 2,697 register.
Under-80s BP control and lipid therapy lag.
Under-80s blood pressure control is 60.6% (England 67.8%) and QRISK ≥ 20% lipid therapy is 56.9% (England 63.6%), which may reflect recall gaps.
COPD reviews and 80+ BP control improved.
Over 2023 to 2025, COPD annual reviews rose +17.6% to 71.5% (England +2.8%) and 80+ hypertension control rose +15.0% (England +2.2%).
Population, age and ethnicity
Older than England, the PCN includes 8,599 older patients and 35 catchment care homes
Across 42,016 registered patients, 20.5% (8,599) are aged 65+, below Folkestone and Hythe (25.7%) but above NHS Kent and Medway ICB (19.9%) and England (17.9%). Children aged 0-17 represent 19.7% (8,272), above Folkestone and Hythe (17.4%), below the ICB (20.7%) and in line with England (19.6%). The non-White ethnic minority share is 11.1%, with Asian or Asian British residents at 6.1% (Census usual residents), above Folkestone and Hythe (3.9%) and the ICB (4.7%) but below England (9.6%). List size is projected to grow 4.3% by 2030 under an unverified methodology.
Age profile
65+: ICB 19.9%, England 17.9%
Ethnicity
Older people · falls rows are Folkestone and Hythe local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Folkestone & Hythe LA) | 1,699 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 80.1% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 57.2% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Folkestone & Hythe LA) | 856 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Folkestone & Hythe LA) | 16.0 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation reaches 38.5% PCN-wide and is sharply uneven between practices
The PCN has 38.5% of registered patients living in Core20 areas (average IMD decile 3.9), well above Folkestone and Hythe (21.7%), NHS Kent and Medway ICB (17.1%) and England (21.0%). Modelled weighted practice share (39.5%) differs slightly from the PCN figure (38.5%). Deprivation is sharply uneven across a 62.5 pp practice range: Guildhall Street Surgery (65.7%, 6,547 estimated patients), The New Surgery (56.5%, 5,721) and Manor Clinic (42.0%, 3,933) heavily exceed England, while Sandgate Road records 3.2% (401). Outreach may need targeting toward high-volume practices to manage concentrated disadvantage.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
681
SMI register
1.60% recorded prevalence
416
Learning disability register
0.97% recorded prevalence
35
Care homes, 677 beds
In the PCN catchment
10.2%
Provide unpaid care
Folkestone and Hythe, Census 2021
Recorded learning disability prevalence is 1.0% (416 patients) and severe mental illness is 1.6% (681 patients), above Folkestone and Hythe (0.9% and 1.2%), the ICB (0.6% and 0.9%) and England (0.6% and 1.0%). Catchment care homes comprise 35 sites with 677 beds, though capacity does not establish occupancy or registered resident numbers. With both registers above England and regional benchmarks, annual physical-health checks and care-home liaison may be key clinical.
Severe mental illness: physical health checks
Severe mental illness prevalence is 1.6% (England 1.0%). Annual blood pressure checks reach 78.5% (England 83.4%), with The New Surgery at 73.5% and Guildhall Street Surgery at 77.0%. PCN BMI checks reach 77.9% (England 82.1%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
6,933
Hypertension register
+7.44%
Register growth, 3 yrs
Folkestone and Hythe +5.18% · England +5.60%
+5.67pp
BP control, under 80
≤140/90 · +10.28pp aged 80+
+1,419
More patients by 2030
Forecast 8,352 (18.75%)
Hypertension case-finding and control
Recorded hypertension prevalence is 16.2% (6,933 patients), above England (15.2%) but below Folkestone and Hythe (18.6%) and level with NHS Kent and Medway ICB (16.2%), giving an unadjusted benchmark range of -534 to +868 patients. Recent blood pressure monitoring is 83.5% (England 90.0%, NHS Kent and Medway ICB 87.3%). Blood pressure control in patients aged under 80 is 60.6% (England 67.8%, NHS Kent and Medway ICB 64.6%), with The New Surgery at 55.0%, despite PCN gains over 2023 to 2025 of +10.3% (+5.7 pp; England +3.2%, +2.1 pp). Lower control may reflect titration and recall gaps to verify locally.
Lipids and statins
QRISK ≥ 20% lipid-lowering therapy is 56.9% (England 63.6%, NHS Kent and Medway ICB 61.4%). In patients with diabetes aged 40+ without CVD, statin therapy is 66.7% (England 73.2%) after falling 1.3 pp over 2023 to 2025 (England +1.5 pp). Lower treatment rates may reflect initiation gaps across eligible cohorts to audit locally.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 57,638 | £1.90 | £1.90 | £1.86 | £109,512 |
| Cardiovascular (all), 2025 | 85,001 | £5.12 | £3.57 | £3.33 | £435,205 |
In 2026, 57,638 lipid-regulating items were prescribed at £1.90 per item (England £1.86, Folkestone and Hythe £2.17, NHS Kent and Medway ICB £1.90), spending £2,306 more than at England's unit cost across 57,638 items, with no difference from NHS Kent and Medway ICB's unit cost. Adult prescribing reached 1,708 items per 1,000 (England 4,100).
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−8.34%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−4.25%
Asthma prevalence, PCN 3-yr % change
COPD annual reviews rose +17.6% over 2023 to 2025 to 71.5% (England 76.4%, +2.8%). Asthma reviews fell 8.3% over 2023 to 2025 (England +4.4%) to 57.2% (England 65.7%), leaving an estimated scale of 1,155 unreviewed patients on the 2,697 register. At The New Surgery, asthma reviews were 46.5%. Asthma management items prescribed per 1,000 aged 5-19 reached 1,705 (England 1,488). The drop in asthma reviews alongside elevated youth prescribing may reflect review recall gaps to audit locally.
Cancer register and children's immunisation
Cancer prevalence is 4.5% (1,912 patients; England 3.8%). In Q1 2025/26 age-five MMR coverage, dose 1 is 92.3% and dose 2 is 84.6%, showing a 7.7 pp dose difference, below the 95.0% target. At Guildhall Street Surgery, dose 2 is 63.2% compared with 78.9% for dose 1 (a 15.7 pp difference). The second-dose gap may reflect pre-school recall gaps to verify locally.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Kent and Medway ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,630
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Kent and Medway ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 82.1% | 85.4% | 23% | 1,509 |
| Prostate | 54.4% | 53.2% | 37% | 1,435 |
| Lung | 29.4% | 33.8% | 21% | 1,109 |
| Bowel | 48.2% | 47.0% | 29% | 1,013 |
| Skin cancer | 87.5% | 87.8% | 23% | 562 |
In NHS Kent and Medway ICB, 55.6% of cancers with a known stage were diagnosed at stage 1 or 2 in 2022 (England 55.3%), 19.4 pp below the 75.0% national ambition by 2028, requiring an estimated 1,627 extra early-stage cases annually across the ICB. Early-stage share rose 2.2 pp between 2013 and 2022, while known-stage completeness was 63.6% (8,384 of 13,189). In the PCN, breast screening coverage is 62.1% (England 69.9%) despite a three-year rise of +16.6% (England +8.4%). Cervical screening is 64.5% (England 66.8%), falling to 58.3% at Guildhall Street Surgery and 61.0% at The New Surgery. Lower screening uptake may delay early cancer detection.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In provisional July 2026 data for East Kent Hospitals University NHS Foundation Trust, 70.0% of pathways met the 62-day cancer referral to treatment standard, 15.0 pp below the 85.0% standard (ICB 75.9%, England 71.2%). The 28-day faster diagnosis standard reached 71.3%, 3.7 pp below the 75.0% standard (England 79.3%). Combined 31-day treatment achieved 96.7% (96.0% standard). On provider waiting lists, 63.0% of patients waited 6+ weeks for non-obstetric ultrasound (England 19.6%) and 47.6% for MRI (England 21.4%).
| Pathways within standard (%) | East Kent | East Sussex Healthcare | Maidstone and Tunbridge Wells | Kent and Medway ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 71.28 | 84.20 | 81.78 | 76.78 | 79.32 |
| 31-day treatment (96%) | 96.67 | 98.19 | 98.35 | 95.84 | 92.50 |
| 62-day referral to treatment (85%) | 70.01 | 67.04 | 87.43 | 75.93 | 71.16 |
| Diagnostic waits over 6 weeks (%) | East Kent | East Sussex Healthcare | Maidstone and Tunbridge Wells | England |
|---|---|---|---|---|
| MRI | 47.58 | 6.48 | 0.92 | 21.40 |
| CT | 37.45 | 0.48 | 0.51 | 9.92 |
| Echocardiography | 14.17 | 21.94 | 2.57 | 28.48 |
| Colonoscopy | 9.58 | 0.74 | 19.80 | 30.83 |
| Gastroscopy | 22.16 | 0.31 | 24.03 | 29.02 |
| All 15 DM01 tests | 48.38 | 5.27 | 6.42 | 23.14 |
| Community services activity | Kent residents | Kent and Medway ICB |
|---|---|---|
| Care contacts | 210,170 | 254,055 |
| Referrals | 59,360 | 68,085 |
| Patients with a contact | 60,605 | 72,060 |
Community services (residents of Kent), Jun 2026 (provisional). In provisional Community Services Dataset figures for Jun 2026, 65.8% of community contacts among Folkestone and Hythe residents were with adults aged 65+ (138,250 of 210,170 contacts). These figures describe wider borough resident activity rather than PCN-level delivery.
Practice variation and patient experience
Practices achieve maximum clinical QOF points but show substantial variation in vaccination and immunisation
In 2025/26, all four practices achieved 100.0% in the QOF clinical domain (England 97.1%). Vaccination and immunisation achievement trails England (55.2%), spanning 24.1 pp from 22.6% at Guildhall Street Surgery to 46.7% at Sandgate Road. Overall QOF achievement ranges from 90.3% at Guildhall Street Surgery to 94.0% at Sandgate Road (England 92.5%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Guildhall Street | 114 | 65.7 | 34.6% | 70.7% | 74.1% |
| Manor Clinic | 118 | 42.0 | 43.9% | 68.8% | 69.0% |
| Sandgate Road | 107 | 3.2 | 24.7% | 72.7% | 56.9% |
| The New Surgery | 89 | 56.5 | 36.2% | 61.0% | 48.9% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Ten of 25 measures trail England despite three-year gains in COPD reviews
Over 2023 to 2025, 10 of 25 monitored measures trailed England's three-year trend. The widest relative lags were in asthma annual reviews, falling 8.3% (England +4.4%) to a current level of 57.2% (England 65.7%), and dementia prevalence, which fell 1.7% while England rose +6.0%. Conversely, clear strengths emerged: COPD annual reviews increased +17.6% (England +2.8%), blood pressure control among hypertensive patients aged 80+ rose +15.0% (England +2.2%), and psychosis alcohol recording gained +14.4 pp (England +5.4 pp) to 81.5% (England 81.8%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Asthma reviews
Dementia register
Asthma register
Diabetes statin (no CVD)
QRISK statin treatment
COPD reviews
BP control, 80+
Alcohol record (psychosis)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Folkestone and Hythe | Asset | PCN | Folkestone and Hythe |
|---|---|---|---|---|---|
| Care homes (catchment) | 35 (677 beds) | n/a | Schools (catchment) | 55 | n/a |
| Children's centres | 4 | 8 | Places of worship | 34 | 78 |
| Libraries | 4 | 8 | Food banks (VCS) | 1 | 1 |
| Day centres (VCS) | 2 | 2 | Children and young people (VCS) | n/a | 1 |
| Carers support groups (VCS) | n/a | 1 | Primary schools (LA maintained) | 9 | 21 |
| Primary academies | 9 | 15 | Special schools | 1 | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma annual review recall
Asthma annual reviews are 57.2% (England 65.7%; The New Surgery 46.5%) after falling 8.3% (-5.2 pp) over 2023 to 2025, an estimated scale of 1,155 unreviewed on the 2,697 register. For discussion: the PCN could run structured asthma recall using a single template, flexible slots and inhaler prescribing reviews. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Cardiovascular BP and lipid review
On the 6,933 hypertension register (16.2%), under-80s BP control is 60.6% (England 67.8%; The New Surgery 55.0%), recent readings 83.5% (England 90.0%) and QRISK ≥ 20% lipid therapy 56.9% (England 63.6%). For discussion: the PCN could run pharmacist-led recall clinics to review uncontrolled hypertension and initiate lipid-lowering therapy. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
SMI physical health check outreach
On the 681-patient SMI register (1.6% vs 1.0% in England; 48.2% of the borough register), annual BP checks are 78.5% (England 83.4%; The New Surgery 73.5%, Guildhall Street Surgery 77.0%). For discussion: the PCN could offer combined physical health check clinics, audit coding, and align outreach with system partners. Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Targeted Core20 practice outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Physical health review outreach (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension recall and review (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school MMR recall audit (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Targeted cervical screening recall (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Structured asthma annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN & Practice |
| Option 2 · Cardiovascular BP and lipid review (p12) | Hypertension register · Hypertension: QOF prevalence · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN & Practice |
| Option 3 · SMI physical health check outreach (p12) | Severe mental illness register · Severe mental illness: QOF prevalence · SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
